MUSTANG BIO, INC.

Mustang Bio is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company develops CAR-T immunotherapies and gene therapies, including CD20-targeted CAR T cell therapies and lentiviral gene therapies for X-linked severe combined immunodeficiency (X-SCID). Mustang Bio operates a CAR T cell therapy manufacturing facility in Worcester, Massachusetts, and has partnered with leading academic medical institutions to advance its clinical pipeline. The company is a partner company of Fortress Biotech (NASDAQ: FBIO).